Akabane Miho, Nakamura Yuki, Miki Katsuyuki, Yokoyama Takayoshi, Ubara Yoshifumi, Ishii Yasuo
Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Transplant Proc. 2020 Jul-Aug;52(6):1680-1683. doi: 10.1016/j.transproceed.2020.01.135. Epub 2020 Apr 24.
Renal transplantation in patients with autosomal dominant polycystic kidney disease (ADPKD) remains a feasible option because no recurrence has been reported. Transcatheter arterial embolization (TAE) for patients with ADPKD is performed to control infection, pain, or bleeding and can help reduce kidney volume. However, nephrectomy may be needed for inadequate kidney shrinkage. The effects of these procedures performed before transplantation on transplant outcomes or kidney functions are not discussed. We retrospectively evaluated the effectiveness of nephrectomy and TAE before transplantation.
Forty-four patients who underwent renal transplantation in our center between 2008 and 2018 were classified into 4 groups according to whether nephrectomy or TAE was performed. We collected information on sex, age, type of transplantation, history of nephrectomy or TAE, renal function, postoperative complications, graft acceptance, and survival rates.
Of the 17 patients who underwent TAE and those who did not, 8 and 7 underwent nephrectomy, respectively; 16 underwent bilateral TAE and primitive transplantation. The patients who underwent both nephrectomy and TAE had significantly better kidney function than those who underwent neither. With TAE alone, without nephrectomy, the mean volume reduction rate was 23.5% and 28.4% on the left and right, respectively; in patients who underwent neither procedure, the mean volume reduction rates were 24.8% and 28.4%, respectively.
Patients who underwent both nephrectomy and TAE had better renal function than those in any other group. However, if the recipient's pelvis has sufficient space, nephrectomy is unnecessary because the kidney volume decreases after transplantation by approximately 25%.
常染色体显性多囊肾病(ADPKD)患者的肾移植仍是一种可行的选择,因为尚无复发报道。对ADPKD患者进行经导管动脉栓塞术(TAE)可控制感染、疼痛或出血,并有助于减小肾脏体积。然而,肾脏缩小不足时可能需要进行肾切除术。尚未讨论这些移植前手术对移植结局或肾功能的影响。我们回顾性评估了移植前肾切除术和TAE的有效性。
2008年至2018年在我们中心接受肾移植的44例患者根据是否进行肾切除术或TAE分为4组。我们收集了有关性别、年龄、移植类型、肾切除术或TAE病史、肾功能、术后并发症、移植物接受情况和生存率的信息。
在接受TAE的17例患者和未接受TAE的患者中,分别有8例和7例接受了肾切除术;16例接受了双侧TAE和原位移植。同时接受肾切除术和TAE的患者的肾功能明显优于未接受这两种手术的患者。仅进行TAE而未进行肾切除术时,左、右肾平均体积缩小率分别为23.5%和28.4%;未进行这两种手术的患者,左、右肾平均体积缩小率分别为24.8%和28.4%。
同时接受肾切除术和TAE的患者的肾功能优于其他任何组。然而,如果受者的盆腔有足够空间,则无需进行肾切除术,因为移植后肾脏体积会减少约25%。